Structure Therapeutics Inc (GPCR) Stock Price, Quote & News

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in pre...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 457 1978

Website: structuretx.com

Address:

601 Gateway Boulevard, Suite 900, South San Francisco, United States

judgeyoung2 Feb. 4 at 3:22 AM

$GPCR where the fuck is the buyout

1 · Reply

SBL71 Feb. 3 at 8:26 PM

$GPCR

1 · Reply

keylimepie2 Feb. 3 at 6:27 PM

$GPCR Kyle are you okay buddy?

0 · Reply

keylimepie2 Feb. 3 at 5:35 PM

$VKTX But by Kyle’s logic this doesn’t apply to $GPCR because he invests in them

0 · Reply

StockMktGuru Feb. 3 at 5:19 PM

$ALT Obesity competitors should get hit on NVO. Can understand why $LLY, $VKTX and $GPCR should get clobbered but doesn't explson why MASH drug companies get hit.

2 · Reply

Theflash88 Feb. 3 at 4:53 PM

$GPCR Chasing out the weak hands.

0 · Reply

keylimepie2 Feb. 3 at 2:54 PM

$VKTX $VKTX Kyle is invested in $GPCR. Talking trash on this board when his shares are down 7%. Can someone send him a genetic test? He likely has 3 sets of chromosome 21.

2 · Reply

Kylenorth Feb. 3 at 2:48 PM

$GPCR what a gift this morning!! keep loading

0 · Reply

norbertm Feb. 3 at 2:41 PM

$GPCR fat fingers taking profits.

0 · Reply

keylimepie2 Feb. 3 at 2:37 PM

$VKTX $GPCR down 7% wonder why

2 · Reply

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN LLY NVO PFE VKTX

Jan 21, 2026, 10:05 AM EST - 13 days ago

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Jan 15, 2026, 6:21 PM EST - 19 days ago

Structure CEO Ray Stevens talks its obesity drug portfolio

Dec 11, 2025, 4:01 PM EST - 7 weeks ago

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Dec 9, 2025, 11:15 PM EST - 2 months ago

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Dec 9, 2025, 8:30 AM EST - 2 months ago

Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)

Dec 8, 2025, 7:27 PM EST - 2 months ago

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript

Dec 8, 2025, 5:18 PM EST - 2 months ago

Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program

Dec 8, 2025, 4:01 PM EST - 2 months ago

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Dec 8, 2025, 12:46 PM EST - 2 months ago

Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump

Dec 8, 2025, 11:20 AM EST - 2 months ago

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Dec 8, 2025, 8:14 AM EST - 2 months ago

Structure's experimental pill shows 11% weight loss in study, shares up

Dec 8, 2025, 8:00 AM EST - 2 months ago

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Dec 7, 2025, 6:20 PM EST - 2 months ago

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Nov 10, 2025, 6:21 PM EST - 3 months ago

Final Trade: UBER, CRWV, GPCR, DIS

CRWV UBER DIS

Nov 6, 2025, 4:01 PM EST - 3 months ago

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 5, 2025, 6:21 PM EST - 3 months ago

Fast Money: DAL, ROKU, AAPL, GPCR

AAPL ROKU DAL

Sep 10, 2025, 1:54 PM EDT - 5 months ago

Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 6, 2025, 4:01 PM EDT - 6 months ago

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Jun 23, 2025, 6:10 PM EDT - 8 months ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN LLY NVO PFE REGN VKTX XBI

Jun 20, 2025, 7:30 PM EDT - 8 months ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Apr 14, 2025, 10:49 AM EDT - 10 months ago

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

VKTX

Mar 27, 2025, 7:40 AM EDT - 11 months ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN DNLI INSM MRK SWTX

Mar 24, 2025, 6:26 PM EDT - 11 months ago

Structure Therapeutics CEO on latest GLP-1 developments

Mar 24, 2025, 6:23 PM EDT - 11 months ago

Final Trade: PYPL, UBER, NKE, GPCR

NKE PYPL UBER

Mar 20, 2025, 9:28 AM EDT - 11 months ago

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Jan 30, 2025, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Jan 6, 2025, 2:53 PM EST - 1 year ago

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

VKTX

Dec 17, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Dec 5, 2024, 6:17 PM EST - 1 year ago

Structure CEO on the competitive landscape for oral GLP-1 drugs

NVO

Nov 15, 2024, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 13, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Oct 22, 2024, 2:07 PM EDT - 1 year ago

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP SRRK VKTX

Aug 23, 2024, 3:17 PM EDT - 1 year ago

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Jun 11, 2024, 6:37 PM EDT - 1 year ago

Structure Therapeutics CEO on GLP drugs

Jun 7, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Jun 5, 2024, 7:53 PM EDT - 1 year ago

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Jun 3, 2024, 6:27 PM EDT - 1 year ago

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Jun 3, 2024, 4:09 PM EDT - 1 year ago

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Jun 3, 2024, 2:38 PM EDT - 1 year ago

Structure Therapeutics reports promising weight-loss drug data

Jun 3, 2024, 8:42 AM EDT - 1 year ago

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Jun 3, 2024, 7:30 AM EDT - 1 year ago

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

May 7, 2024, 11:33 AM EDT - 1 year ago

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

AMGN LLY NVO ALT AZN VKTX

Apr 16, 2024, 7:09 PM EDT - 1 year ago

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

AMGN AZN LLY NVO PFE SNY VKTX

Mar 9, 2024, 2:30 AM EST - 2 years ago

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

NVO PFE VKTX

Mar 8, 2024, 4:05 PM EST - 2 years ago

Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference

judgeyoung2 Feb. 4 at 3:22 AM

$GPCR where the fuck is the buyout

1 · Reply

SBL71 Feb. 3 at 8:26 PM

$GPCR

1 · Reply

keylimepie2 Feb. 3 at 6:27 PM

$GPCR Kyle are you okay buddy?

0 · Reply

keylimepie2 Feb. 3 at 5:35 PM

$VKTX But by Kyle’s logic this doesn’t apply to $GPCR because he invests in them

0 · Reply

StockMktGuru Feb. 3 at 5:19 PM

$ALT Obesity competitors should get hit on NVO. Can understand why $LLY, $VKTX and $GPCR should get clobbered but doesn't explson why MASH drug companies get hit.

2 · Reply

Theflash88 Feb. 3 at 4:53 PM

$GPCR Chasing out the weak hands.

0 · Reply

keylimepie2 Feb. 3 at 2:54 PM

$VKTX $VKTX Kyle is invested in $GPCR. Talking trash on this board when his shares are down 7%. Can someone send him a genetic test? He likely has 3 sets of chromosome 21.

2 · Reply

Kylenorth Feb. 3 at 2:48 PM

$GPCR what a gift this morning!! keep loading

0 · Reply

norbertm Feb. 3 at 2:41 PM

$GPCR fat fingers taking profits.

0 · Reply

keylimepie2 Feb. 3 at 2:37 PM

$VKTX $GPCR down 7% wonder why

2 · Reply

keylimepie2 Feb. 3 at 2:36 PM

$GPCR WHAT HAPPENED??

0 · Reply

norbertm Feb. 3 at 2:14 PM

$GPCR unusual selling pressure with volume in AH last evening and to a smaller degree this PM. Couldn’t find any news explaining these moves. I’ll take it as a reverse omen to fly to our next target 🤷‍♂️

1 · Reply

outlawinvestor1 Feb. 2 at 7:06 PM

$NVO updated cagrisema results today don't provide a clearly superior product vs $LLY zepbound - they are essentially tied (advantages/disadvantages on both sides). with that said, novo now has a competitive product for patients that need something stronger than wegovy. i think the rub for both zepbound, cagrisema and any other future next-gen injectable is generic wegovy will take most of market share due to strong preference from payors. insurers will continue to be the barrier to adoption of newer more expensive treatments. however, i think the next frontier for branded premium priced obesity/diabetes treatment can still be ORAL. $GPCR $VKTX

1 · Reply

Kylenorth Feb. 2 at 3:45 PM

$GPCR all time highs coming!!! BO in the next couple months!! strong AF!!!

0 · Reply

outlawinvestor1 Feb. 2 at 10:57 AM

$NVO is undervalued and i will continue to buy as much as possible. $VKTX is also starting to look attractive as its valuation continues to fall - think i'll start a position soon. i'll hold my position in $GPCR, but won't add. $LLY

0 · Reply

Tfizzle Feb. 1 at 8:04 PM

$ALT $GPCR $LLY $MDGL $NVO

1 · Reply

GreenEnergy2022 Feb. 1 at 7:14 PM

$ALT Jefferies out with PT 28$ 400% !! LFG, tomorrow we rally. Most undervalued GLP1 in the Obesoty/MASH space $LLY $NVO $GPCR $MDGL

3 · Reply

BioRich Feb. 1 at 6:24 AM

$ALT So those cowardly bashing $GUTS, did you know that they have compelling data for MASH/MASLD related conditions? Oh, and a much faster path to market? Wouldn't it be something if $GUTS makes it to market with multiple indications faster than $ALT completing a Phase 3 trial (if they actually pursue it)? Wouldn't it be something if $SNY was talking about $GUTS when they were talking about potential acquisitions with multiple, differentiated, indications (paraphrased)? I still believe the $GUTS, $IVA, $GPCR trifecta builds $SNY an Obesity/Fibrosis/MASH/WL Retention powerhouse. Can't wait for this story to play out. Cheers! ~The Mayor Confidently Bearish $ALT Confidently Bullish $GUTS Bullish $SNY Confidently Bullish $IVA Confidently Bullish $GPCR

1 · Reply

ChessGM Jan. 30 at 7:49 PM

$GPCR A clean way to “rationalize” the buyout thesis in one sentence Structure can be framed as: a de-risked oral GLP-1R program plus a GPCR discovery platform in a market where strategic buyers are paying up for scarce, scalable cardiometabolic assets.

0 · Reply

Kylenorth Jan. 30 at 6:36 PM

$GPCR paid 10x on calls!!! sexy!! BO coming this year

0 · Reply

notreload_ai Jan. 30 at 4:27 PM

$GPCR , which makes next-generation oral obesity drugs, is becoming a top takeover target for big pharma. As obesity drugs boom, large companies are buying innovators to replace expiring patents and enter this fast-growing market. https://www.axios.com/pro/biotech-deals/2026/01/30/structure-therapeutics-pharmas-next-buyout-glp1

0 · Reply

blocktrade Jan. 30 at 3:55 PM

$GPCR I thought selling 25% at 92 and rolling the funds into $VKTX was a good idea. 🤡 . This is like selling Tesla and putting the funds in lcid

0 · Reply

Market Cap	5.37B
Revenue (ttm)	0.00
Net Income (ttm)	-122.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,440,500
Avg Vol	1,654,666
Day's Range	N/A - N/A
Shares Out	60.68M
Stochastic %K	13%
Beta	-2.05
Analysts	Strong Sell
Price Target	$107.80